Ruth O’Regan, MD, professor and head, Hematology, Medical Oncology and Palliative Care, shared her perspective on emerging treatments for HER2-positive breast cancer in a video appearing on OncLive, a news outlet for oncology professionals. 

“I think for HER2-positive cancers, what we’re going to see is some interest in using checkpoint inhibitors, particularly for ER-negative, HER2-positive cancers,” she said. 

Explaining that some ER-negative, HER2-positive cancers have a luminal A phenotype, Dr. Regan said, “I think it would be interesting to see if you could focus specifically on those luminal A, HER2-positive cancers and see if you could get away with HER2-directed therapy,” instead of chemotherapy.

Resources:

• "Dr. O'Regan Discusses the Future of Treatment in HER2+ Breast Cancer," OncLive, May 16, 2017